CSTL Stock Up 18% after 5-Day Win Streak
Castle Biosciences (CSTL) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 18% return. The company has gained about $124 Mil in value over the last 5 days, with its current market capitalization at about $700 Mil. The stock remains 9.2% below its value at the end of 2024. This compares with year-to-date returns of 9.1% for the S&P 500.
CSTL provides diagnostic and prognostic testing services for dermatological cancers, including a multi-gene expression profile test to assess metastasis risk in invasive cutaneous melanoma patients. After this rally, is CSTL still a buy – or is it time to lock in gains? Deep dive with Buy or Sell CSTL.
Comparing CSTL Stock Returns With The S&P 500
The following table summarizes the return for CSTL stock vs. the S&P 500 index over different periods, including the current streak:
- Better Value & Growth: LRCX, AMAT Lead Enphase Energy Stock
- Stronger Bet Than Hyatt Hotels Stock: RCL, BKNG Deliver More
- Is the Market Overlooking the Turnaround in Covista Stock?
- Stride Stock Is Down, But Is The Business Actually Broken?
- Without Starship, Will SpaceX Stock Fall Apart?
- Years of Rewards: $28 Bil From Medtronic Stock
| Return Period | CSTL | S&P 500 |
|---|---|---|
| 1D | 0.8% | -0.7% |
| 5D (Current Streak) | 17.7% | -0.4% |
| 1M (21D) | 65.3% | 2.8% |
| 3M (63D) | 48.8% | 8.1% |
| YTD 2025 | -9.2% | 9.1% |
| 2024 | 23.5% | 23.3% |
| 2023 | -8.3% | 24.2% |
| 2022 | -45.1% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 36 S&P constituents with 3 days or more of consecutive gains and 93 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 14 | 62 |
| 4D | 13 | 13 |
| 5D | 5 | 3 |
| 6D | 0 | 15 |
| 7D or more | 4 | 0 |
| Total >=3 D | 36 | 93 |
Key Financials for Castle Biosciences (CSTL)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $219.8 Mil | $332.1 Mil |
| Operating Income | $-68.0 Mil | $8.7 Mil |
| Net Income | $-57.5 Mil | $18.2 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $88.0 Mil | $86.2 Mil |
| Operating Income | $-27.9 Mil | $-4.3 Mil |
| Net Income | $-25.8 Mil | $4.5 Mil |
While CSTL stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.